Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.
Joshua A. Roth, PhD, MHA
Advertisement
Articles by Joshua A. Roth, PhD, MHA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
2
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5